Voltage Imaging of Cardiac Cells and Tissue Using the Genetically Encoded Voltage Sensor Archon1

Sanaya N. Shroff, Shoshana L. Das, Hua-an Tseng, ..., John A. White, Christopher S. Chen, Xue Han

chencs@bu.edu (C.S.C.)
xuehan@bu.edu (X.H.)

HIGHLIGHTS
Genetic sensor Archon1 reports membrane voltage in hiPSC-derived cardiomyocytes

Archon1 monitors action potentials in 2D and 3D cardiac tissue with high sensitivity

Archon1 repeatedly monitored voltage in the same cells and over extended time periods

Voltage dynamics of multiple cells were recorded simultaneously with Archon1
Voltage Imaging of Cardiac Cells and Tissue Using the Genetically Encoded Voltage Sensor Archon1

Sanaya N. Shroff,1,4 Shoshana L. Das,1,2,3,4 Hua-an Tseng,1 Jad Noueihed,1 Fernando Fernandez,1 John A. White,1 Christopher S. Chen,1,3,* and Xue Han1,5,*

SUMMARY
Precise measurement of action potentials (APs) is needed to observe electrical activity and cellular communication within cardiac tissue. Voltage-sensitive dyes (VSDs) are traditionally used to measure cardiac APs; however, they require acute chemical addition that prevents chronic imaging. Genetically encoded voltage indicators (GEVIs) enable long-term studies of APs without the need of chemical additions, but current GEVIs used in cardiac tissue exhibit poor kinetics and/or low signal to noise (SNR). Here, we demonstrate the use of Archon1, a recently developed GEVI, in hiPSC-derived cardiomyocytes (CMs). When expressed in CMs, Archon1 demonstrated fast kinetics comparable with patch-clamp electrophysiology and high SNR significantly greater than the VSD Di-8-ANEPPS. Additionally, Archon1 enabled monitoring of APs across multiple cells simultaneously in 3D cardiac tissues. These results highlight Archon1’s capability to investigate the electrical activity of CMs in a variety of applications and its potential to probe functionally complex in vitro models, as well as in vivo systems.

INTRODUCTION
The measurement of electrical potential and conduction in the heart is important for understanding how electrical signals propagate through cardiac tissue in both healthy and diseased conditions. Although numerous methods exist for monitoring whole-heart voltage (EKG, EPS, etc.), few techniques examine the properties at the individual cell level within cardiac tissue. Intracellular calcium release, triggered by action potentials (APs), has long been used to study mechanisms such as excitation-contraction coupling and as a proximal measurement for signal propagation (Bers, 2002, 2008; Eisner et al., 2017; Hobai and O’Rourke, 2001). However, calcium does not provide insight into membrane voltage dynamics and individual AP properties, which may be altered in biological, pharmacological, or pathological states (Leyton-Mange and Milan, 2014; Leyton-Mange et al., 2014; Oliviari et al., 1979; Peng et al., 2010; Sanguinetti and Jurkiewicz, 1991; Sanguinetti et al., 1991; Shaheen et al., 2018; Shinnawi et al., 2015; Song et al., 2015). Recent attempts to study cardiac membrane potential have made use of voltage-sensitive dyes (VSDs) such as the ANEPPS series or the PGH series (Entcheva and Bien, 2006; Herron et al., 2012; Hortigon-Vinagre et al., 2016; Panakova et al., 2010; Salama et al., 2005; Salama and Morad, 1976). Although many of these VSDs have the time resolution necessary to capture AP dynamics of cardiac cells, they often suffer from poor signal-to-noise ratio (SNR) and membrane localization and are often cytotoxic (Herron et al., 2012; Hou et al., 2014). In addition, by nature, VSDs are transient and must be reapplied to samples, which hinders long-term studies; they also lack the ability to label specific subpopulations.

Genetically encoded voltage indicators (GEVIs), which have been successfully utilized in a similarly electrically excitable cell population, neurons (Abdelfattah et al., 2019; Adam et al., 2019; Chamberland et al., 2017; Flytzanis et al., 2014; Gong et al., 2014, 2015; Hochbaum et al., 2014; Jin et al., 2012; Lou et al., 2016; Pratkevich et al., 2018; St-Pierre et al., 2014; Villette et al., 2019; Zou et al., 2014), have recently been deployed in cardiac tissue to overcome the shortcomings of VSDs (Hou et al., 2014; Johnston et al., 2018; Leyton-Mange et al., 2014). Although GEVIs such as ArcLight, Mermaid, or the VSFP series have been successfully applied to study arrhythmias, as well as aid in cellular phenotyping, these GEVIs lack the time resolution, sensitivity, and SNR to capture voltage dynamics under various conditions (Chang Liao et al., 2015; Leyton-Mange et al., 2014; Mutoh et al., 2009; Tsutsui et al., 2010; van Opbergen et al., 2018). For example, ArcLight, a commonly used GEVI, has slow kinetics, which hinders its ability to capture the characteristic upstroke morphology of cardiac APs and any perturbations to this upstroke such as...
those caused by diseases or drugs (Lee et al., 2017; Leyton-Mange et al., 2014; Nakajima et al., 2016; Storace et al., 2016). In contrast, the GEVI VSFP3.1 has relatively fast kinetics (activation time $C_24^{1.3} ms$) but displays fluorescence changes of only 0.5% per 100 mV, which impedes monitoring of subthreshold fluctuations and contributes to a very low SNR (Kaestner et al., 2015; Lundby et al., 2008). Many of these GEVIs thus suffer from this dichotomy between superior kinetics and sensitivity.

Recently, Piatkevich et al. developed a high-performance GEVI called Archon1, a far-red fluorescent plasma transmembrane protein evolved from the Arch3 opsin, with fluorescence emission linearly dependent on membrane voltage (Piatkevich et al., 2018). Archon1 exhibits high temporal resolution, sensitivity, and brightness under simple one-photon widefield microscopy, which enabled imaging of neural activity in mouse cortical brain slices, whole zebrafish, and $C. elegans$ (Piatkevich et al., 2018). Archon1’s fast kinetics and linear fluorescence-voltage relationship resulted in fluorescence traces that closely matched simultaneously recorded electrophysiology. Since Archon1 does not need chemical cofactors, the sensor showed no phototoxicity and retained photostability for up to 800 s in cultured mouse neurons (Piatkevich et al., 2018). In addition, Archon1 demonstrated excellent membrane localization and did not alter membrane resistance, capacitance, or resting potential as compared with non-expressing cells. Its far-red excitation is also compatible with blue-light-driven optogenetics enabling all-optical electrophysiology (Piatkevich et al., 2018, 2019). These features of Archon1, along with its easily adaptable one-photon widefield imaging setup, make it an ideal GEVI candidate to deploy in other electrically dependent systems. Here, we demonstrate Archon1’s utility for monitoring cardiac APs in both 2D cell culture and 3D tissue environments under a variety of biologically relevant conditions.

RESULTS
Characterization of Archon1 in iPSC-Derived Cardiomyocytes

Archon1 was expressed in 2D monolayers of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs) using both Cre-dependent CAG-Archon1-KGC-EGFP-ER2 (Archon1) and CMV-Cre AAV (Figure 1A) 5–7 days after spontaneous beating was observed. CM membrane potential was recorded optically at 100 Hz using a scientific cMOS camera ($\lambda_{ex} = 637$ nm). Archon1 fluorescence changes exhibited typical cardiac AP waveforms with clearly identifiable phases (Figures 1B and 1C; i: resting potential, ii: peak depolarization, iii: end of repolarization; Video S1). Changes in intensity were not due to motion from cellular contraction as indicated by lack of fluorescence changes in the GFP channel (Video S2), as compared with the Archon1 channel (Video S1). In order to quantify AP duration, we calculated rise time...
(t_{rise}, defined by 10%–90% of the valley-to-peak duration), APD50 (AP duration at 50% repolarization), and APD90 (AP duration at 90% repolarization) (Figure 1D, see Transparent Methods). Without electrical stimulation, APD90 values ranged from 345 to 1,210 ms (n = 31 cells, 880 ± 218 ms, mean ± standard deviation, Figure 1C right). We then evoked APs by electrically pacing CMs at 0.5, 1, and 2 Hz and found that Archon1 fluorescence faithfully followed electrical stimulation (Figure 1E; respective APD90 distributions, Figure 1F).

Together, these results demonstrate that Archon1 can robustly capture AP dynamics and waveform morphology, and this capability is maintained at higher frequencies.

To quantify Archon1 performance, we conducted patch-clamp electrophysiology while simultaneously optically recording Archon1 fluorescence of CMs. We found that membrane voltage recorded via Archon1 fluorescence matched well with that recorded via electrophysiology (representative overlay in Figure 2A). Archon1 fluorescence was linearly correlated with electrically recorded membrane potential (Ephys; acquired at 10–20kHz), down-sampled electrophysiology (Ephys-DS; same electrophysiology data down-sampled to 100 Hz to match the acquisition rate of Archon1), and Archon1 (Archon1; acquired at 100 Hz) from n = 17, 17, and 67, cells, respectively. *: p < 0.05 in two-tailed Student’s t test, ns: p > 0.05 in two-tailed Student’s t test.

To further characterize the performance of Archon1, rise times were calculated across all CMs recorded with electrophysiology and Archon1 (n = 17 cells for electrophysiology, 67 cells for Archon1; Figure 2D). The rise time of Archon1 (29.8 ± 13.2 ms, mean ± standard deviation) was slightly longer than that of electrophysiology (15.9 ± 5.6 ms, mean ± standard deviation; Ephys ↔ Archon1: p = 5.8 × 10⁻⁵; two-tailed Student’s t test; Table S1). To examine how these kinetic measures are influenced by the difference
in data acquisition rates, 10–20 kHz for electrophysiology versus 100 Hz for Archon1, we down-sampled the same electrophysiology data to 100 Hz to match the optical imaging frame rate. We obtained a rise time of 23.3 ± 9.4 ms (mean ± standard deviation) for down-sampled electrophysiology traces, which is no longer significantly different from Archon1 (p = 0.06, two-tailed Student’s t test; Figure 2D).

We also compared Archon1 with a widely used red membrane-targeted voltage dye, Di-8-ANEPPS (λex = 470nm; Figure 2E and Video S3). APD90 values were compared per cell between Di-8-ANEPPS and Archon1 and showed a nearly 1:1 correlation (least-squares regression line: y = 1.001x – 0.003, R² = 0.954; Figure 2F; n = 29 cells). To compare performances across electrophysiology, Di-8-ANEPPS, and Archon1, we calculated the corresponding SNR (defined as the valley-to-peak amplitude divided by the standard deviation of the noise) for each method (n = 17, 29, 67 cells, respectively; Figure 2G). SNR was significantly different between all groups, with Archon1’s SNR (Archon1: 30.7 ± 9.3, mean ± standard deviation) significantly higher than that of Di-8-ANEPPS (Di-8-ANEPPS: 20.2 ± 6.1, mean ± standard deviation; Archon1 ↔ Di-8-ANEPPS: p = 4.87 × 10⁻⁸, two-tailed Student’s t test) but significantly lower than that of electrophysiology (Ephys: 40.4 ± 13.5, mean ± standard deviation; Ephys ↔ Archon1: p = 8.3 × 10⁻⁹, two-tailed Student’s t test; Table S1). Together, these results demonstrate that Archon1 voltage imaging exhibited comparable kinetics to that achieved via patch-clamp electrophysiology and SNR significantly better than the VSD Di-8-ANEPPS.

Because Archon1 is genetically encoded and optical voltage imaging does not incur mechanical damage to the cell membrane, as with electrophysiology, Archon1 should allow repeated imaging of the same cells. To demonstrate Archon1’s robustness over time, CMs expressing Archon1 were imaged repeatedly at three time points: (t = 0, 1, and 3 h) (n = 14 cells, Figure 2H, example in Figures S2A–S2C). Over repeated recordings, SNR remained constant (36.0 ± 17.7, 34.1 ± 17.1, 35.1 ± 15.6 mean ± standard deviation for t = 0–1.3 h respectively; p = 0.96, repeated measures one-way ANOVA). We also found that Archon1 was highly photo-stable over 5 min of continuous imaging with SNR remaining stable across the recording (Figures S2D–S2F; SNR: 24.67 ± 0.659, 24.72 ± 0.475, 24.56 ± 0.816, mean ± standard deviation, for t = 0–20 s, 100–120 s, 280–300 s, respectively; p = 0.82, repeated measures one-way ANOVA; full statistics in Table S1). Furthermore, CMs expressing Archon1 retained expression months post-infection (see Video S4 for video of Archon1-expressing CM at day 62 after infection). Archon1 is thus capable of monitoring CM APs over extended periods of time, with high fidelity as compared with currently available methods, in cultured 2D monolayers.

**Archon1 Can Reliably Detect Pharmacologically Induced Changes in AP Waveforms**

To examine the sensitivity of Archon1 for detecting changes in AP waveforms, we recorded Archon1-expressing CMs upon the application of two well-characterized ion channel inhibitors, E-4031 and Nifedipine. E-4031 is a hERG K⁺ channel inhibitor that prolongs the refractory period of the cardiac AP (Peng et al., 2010; Sanguinetti et al., 1991). Nifedipine, on the other hand, is a Ca²⁺ ion channel inhibitor that shortens the AP plateau and overall AP duration and is commonly used to treat hypertension and angina (Olivari et al., 1979). Archon1 fluorescence was imaged from the same cells before and after inhibitor treatment. Treated groups were compared with a DMSO control group (Figure 3A). E-4031 treatment of 2D monolayers at increasing concentrations (3, 10, 30 nM) showed concentration-dependent prolongation of APs (Figure 3B). We compared the mean APD90 before and after E-4031 treatment for all concentrations and observed increasing %ΔAPD90 with increasing E-4031 concentration (mean ± standard deviation, n = 10; 3 nM: 25.2 ± 12.2%, 10 nM: 43.2 ± 8.9%, 30 nM: 55.2 ± 8.1%; full statistics in Table S2) in comparison with the %ΔAPD90 of the DMSO control (n = 10, 1.7% ± 3.6%), consistent with previous studies (Faivre et al., 1999; Hortigon-Vinagre et al., 2016; Ma et al., 2011; Maddah et al., 2015; Peng et al., 2010) (Figure 3D). Nifedipine treatment of 2D monolayers at increasing concentrations (10, 30, 100 nM) also showed the expected concentration-dependent shortening of AP length (Figure 3E). Comparison of the mean APD50 before and after treatments for all three concentrations showed an inverse relationship with %ΔAPD50 and Nifedipine concentration (n = 10; 10 nM: −7.3 ± 2.0%, 30 nM: −11.4 ± 1.9%, 100 nM: −25.0 ± 4.4%, n = 10), compared with the DMSO control (n = 10, 1.9 ± 4.3%) (Figure 3E; Table S2), consistent with previous studies that have performed similar measurements (Hortigon-Vinagre et al., 2016; Ma et al., 2011; Maddah et al., 2015; Scheel et al., 2014). Thus, Archon1 is capable of capturing changes in AP waveform morphology in 2D monolayers.

**Archon1 Enables Monitoring of Action Potentials within Cardiac Tissues**

Engineered cardiac tissues can provide an optical, structural, and functional context that is more similar to in vivo tissue. The use of engineered cardiac tissues, particularly with iPSC-derived CMs, has been shown to increase both the structural and functional maturity of CMs, providing better models compared with more simple 2D...
monolayer systems (Nunes et al., 2013; Ronaldson-Bouchard et al., 2018; Tu et al., 2018; Zimmermann et al., 2002).

To demonstrate Archon1’s ability to measure the APs of single cells embedded within a tissue, we constructed engineered cardiac tissues containing Archon1-expressing CMs alongside a stromal cell population (Figure 4A left, Video S5; see Transparent Methods). The same Cre-recombinase system (Figure 1A) was used for controlled stochastic labeling of CMs to enable optical isolation of individual cells within the engineered tissues. Single CMs expressing Archon1 within the tissues were optically identified via EGFP fluorescence and their APs recorded in the far-red Archon1 fluorescence channel (Figure 4A right, 4B).

Across three unpaced tissues, APD90 ranged from 360 to 890 ms (mean ± standard deviation: 655 ± 143 ms; range: 530 ms), with cells from individual tissues more closely clustered (range: 321, 379, 442 ms and n = 5, 7, 4).

Figure 3. Archon1 Can Reliably Detect Changes in AP Waveforms Induced by K⁺ and Ca²⁺ Ion Channel Inhibitors
E-4031 (K⁺ Channel Blocker) and Nifedipine (Nif; Ca²⁺ Channel Blocker) compared with DMSO control, electrically paced at 1 Hz.

(A–C) (A) Average normalized Archon1 fluorescence intensity traces for DMSO control (n = 10 cells), (B) E-4031 (3, 10, 30 nM; n = 10 cells), and (C) Nifedipine (10, 30, 100 nM; n = 10 cells) before (blue) and after (red) drugs, SD (dotted lines).

(D and E) (D) %ΔAPD90 for E-4031 APs from pre-drug condition. (E) %ΔAPD50 for Nifedipine APs from pre-drug condition where a, b, c, and d represent different statistical groups (all pairs Tukey HSD test). For full statistics see Table S2.

Box plots displayed as described in Figure 1. All optical traces obtained at image acquisition rate of 100 Hz.
cells for Tissue 1, 2, 3, respectively; Figure 4C) demonstrating expected within-tissue homogeneity compared with between-tissue heterogeneity. The SNR and rise time across the three tissues (mean ± standard deviation: 45.7 ± 9.6, and 35 ± 4.3 ms, for SNR and rise time, respectively; Figures 4D and 4E) were comparable with those of 2D monolayers (Figures 2D and 2G), demonstrating that Archon1 is as capable of measuring high-fidelity APs in complex 3D environments and highlighting its potential for use in future in vivo studies.

In order to investigate how CMs interact and synchronize in the tissue, we simultaneously recorded two cells in the same field of view in an unpaced tissue (Figures 4 F and 4G). MYK-461, a cardiac-specific myosin ATPase inhibitor, was used to prevent tissue contraction and associated movement-related optical artifacts (Stern et al., 2016). We found that the two cells’ APs were highly synchronized (Figure 4 G, gray lines), suggesting that they are likely electrically coupled within the tissue, even in the absence of externally applied electrical pacing. In addition, by overlaying normalized single AP waveforms from these two cells, we found that the AP waveform morphology was largely similar, further highlighting their intercellular synchrony (Figure 4 H). The ability to simultaneously record APs from multiple CMs with single-cell precision enables the monitoring of intercellular conductance and/or whole tissue synchrony. Such measurements, when combined with high-speed and ultra-large field of view imaging, could enable future studies to examine how individual cell APs contribute to population dynamics in complex 3D environments and in vivo systems.

**DISCUSSION**

Here, we demonstrate the use of a high-performance GEVI, Archon1, to monitor cardiac action potentials in iPSC-derived cardiomyocytes in 2D monolayers and engineered 3D tissues. Our results demonstrate that Archon1 is capable of robustly reporting AP dynamics under a variety of conditions, including when exposed to electrical pacing and ion channel inhibitors, and has comparable sensitivity and time resolution to patch-clamp electrophysiology—the technically challenging but current gold standard in the field for measuring membrane potential. In addition, Archon1 outperformed the commonly used VSD,
Di-8-ANEPPS, in SNR. In contrast to VSDs, Archon1 is fully genetically encoded, which enabled long-term studies and has the potential for cell-type-specific labeling in in vivo models. Furthermore, the Cre-recombinase system used here enabled optical isolation of CMs within a complex 3D tissue environment, which can be easily translatable to imaging of whole heart slices or cardiac tissue in Cre-transgenic animals. Finally, Archon1 is capable of reporting membrane potential of multiple cells simultaneously, including in 3D tissue environments. This enables population studies, while retaining single-cell precision, allowing measurement of conduction velocity and AP propagation, as well as intercellular phase locking or phase delay. Future studies could examine changes in individual cell voltage dynamics or intercellular propagation around and distal from injury or diseased sites within tissues.

Although we did not take advantage of this utility here, as Archon1 is a far-red indicator, it is compatible with blue-light-driven optogenetic molecules such as channelrhodopsins (Piatkevich et al., 2019). These molecules could be paired to provide simultaneous control and monitoring of cardiac membrane potential. Similarly, Archon1 can be used together with the genetically encoded calcium indicator, GCaMP6, for simultaneous, multicolor imaging of voltage and calcium dynamics (Dempsey et al., 2016; Song et al., 2015). This could enable studies of diseases like Timothy syndrome or heart failure, which affect both voltage dynamics and calcium handling (Beuckelmann et al., 1992; Gwathmey et al., 1987; Kaab et al., 1996; Splawski et al., 2005). Furthermore, the far-red spectrum of Archon1 enables deeper penetration into tissues than those operating at shorter wavelengths, facilitating future in vivo applications.

The genetically encoded nature of Archon1 makes it a useful tool for longer-duration studies of disease mechanisms, such as detecting arrhythmias, which are known to affect AP waveforms or for phenotyping atrial, ventricular, or nodal cells based on waveform morphology (Leyton-Mange et al., 2014; Shaheen et al., 2018; Song et al., 2015). In particular, Archon1 could be used to follow the development of these cell types through differentiation, maturation, etc. or during disease progression (Leyton-Mange et al., 2014; Song et al., 2015). In addition, although we currently transduce CMs with AAVs expressing Archon1, lentiviral particles could additionally be used to create stable cell lines expressing Archon1 for characterization through iPSC differentiation, development, or integration into living tissue.

Finally, Archon1’s capability to monitor CMs in both 2D and 3D environments could assist in the development and evaluation of more functionally mature, biologically relevant engineered cardiac tissues.

**Limitations of the Study**

Photobleaching is often a concern for all optical imaging techniques that deploy fluorescent indicators. However, under 5 min of continuous imaging, Archon1 demonstrated robust monitoring of membrane voltage with no change in SNR, which we expect could extend to tens of minutes. For experiments requiring hours of continuous monitoring, periodic imaging of short durations may be necessary. As GEVIs are engineered to become more sensitive, less light illumination power will be needed to achieve the same SNR and longer imaging studies could be conducted.

In addition, due to current limitations in camera speed, in order to capture an entire CM (typically ~50–100 μm across) within the field of view, the acquisition rate must be limited to ~100 Hz. We have previously shown that Archon1 and its variants can follow millisecond timescale events, such as neuron APs, with high temporal precision at acquisition rates up to 1 kHz (Piatkevich et al., 2018, 2019). As camera technology continues to improve, we hope to be able to conduct such high-speed imaging of larger fields of view containing populations of CMs. Like all non-ratiometric GEVIs or VSDs, Archon1 does not report absolute values of membrane potential, and SNR may vary due to expression levels across individual cells. However, relative membrane potential is still valuable for comparing AP dynamics between different biological states.

In conclusion, Archon1, with its diverse functionality and simple one-photon widefield imaging setup, can be easily adapted for investigating a variety of avenues in cardiac biology and relevant pathology.

**METHODS**

All methods can be found in the accompanying Transparent Methods supplemental file.
DATA AND CODE AVAILABILITY

The data and codes used in this study are available upon reasonable request from the Lead Contact (Xue Han, xuehan@bu.edu). Plasmids used in this study and their sequences are available at Addgene.org (pAAV-CAG-FLEX-Archon1-KGC-EGFP-ER2, Addgene: 108422; pENN.AAV.CMVs.PI.Cre.rBG, Addgene: 105537-AAV9). For correspondence and requests for materials, please contact corresponding authors, xuehan@bu.edu and chencs@bu.edu.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.100974.

ACKNOWLEDGMENTS

We thank Kiryl D. Piatkevich and Edward S. Boyden for providing the rAAV2 CAG-FLEX-Archon1 virus used in all experiments. We thank Paige Cloonan for maintenance of the iPSC lines.

S.N.S. acknowledges funding from the NIH/NIGMS T32 Quantitative Biology and Physiology Fellowship (GM008764) through the Boston University Biomedical Engineering department and from the NIH Ruth L. Kirschstein National Research Service Award (1 F31 NS115421-01). S.L.D. acknowledges funding from the National Science Foundation Graduate Research Fellowship (1122374). C.S.C. acknowledges funding from the National Institutes of Health R01 HL080494 and R01 HL127087. S.N.S., S.L.D., H.T., C.S.C., and X.H. acknowledge funding from the National Science Foundation 1647837. The funders had no role in study design, data collection, and analysis; decision to publish; or preparation of the manuscript.

AUTHOR CONTRIBUTIONS

S.N.S., S.L.D., H.T., C.S.C, and X.H. designed all experiments and interpreted all data. S.L.D performed all cell culture and tissue preparation. S.N.S. and S.L.D. performed all microscopy experiments and ROI selection. J.N. performed optically guided electrophysiology. F.F. and J.A.W. assisted with and supervised the electrophysiology study. H.T. performed voltage trace processing and subsequent analyses. S.N.S. and S.L.D. prepared all figures, and all authors wrote and edited the manuscript. C.S.C. and X.H. oversaw all aspects of the project.

DECLARATION OF INTERESTS

The authors declare no competing financial interests.

Received: September 22, 2019
Revised: February 21, 2020
Accepted: March 5, 2020
Published: April 24, 2020

REFERENCES

Abdelfattah, A.S., Kawashima, T., Singh, A., Novak, O., Liu, H., Shuai, Y., Huang, Y.C., Campagnola, L., Seeman, S.C., Yu, J., et al. (2019). Bright and photostable chemigenetic indicators for extended in vivo voltage imaging. Science 365, 699–704.

Adam, Y., Kim, J.J., Lou, S., Zhao, Y., Xie, M.E., Brinks, D., Wu, H., Mostajo-Radji, M.A., Khelifa, S., Parot, V., et al. (2019). Voltage imaging and optogenetics reveal behaviour-dependent changes in hippocampal dynamics. Nature 569, 413–417.

Bers, D.M. (2002). Cardiac excitation-contraction coupling. Nature 415, 198–205.

Bers, D.M. (2008). Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol. 70, 23–49.

Beuckelmann, D.J., Nabauer, M., and Erdmann, E. (1992). Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85, 1046–1055.

Chamberland, S., Yang, H.H., Pan, M.M., Evans, S.W., Guan, S., Chavarha, M., Yang, Y., Salesse, C., Wu, H., Wu, J.C., et al. (2017). Fast two-photon imaging of subcellular voltage dynamics in neuronal tissue with genetically encoded indicators. Elife 6, https://doi.org/10.7554/eLife.25690.

Chang Liao, M.L., de Boer, T.P., Mutoh, H., Raad, N., Richter, C., Wagner, E., Downie, B.R., Unsold, B., Arooj, I., Streckfuss-Bomeke, K., et al. (2015). Sensing cardiac electrical activity with a cardiac myocyte-targeted optogenetic voltage indicator. Circ. Res. 117, 401–412.

Dempsie, G.T., Chaudhary, K.W., Atwater, N., Nguyen, C., Brown, B.S., McNish, J.D., Cohen, A.E., and Kralj, J.M. (2016). Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging. J. Pharmocol. Toxicol. Methods 81, 240–250.

Eisner, D.A., Caldwell, J.L., Kistamas, K., and Trafford, A.W. (2017). Calcium and excitation-contraction coupling in the heart. Circ. Res. 121, 181–195.

Entcheva, E., and Bien, H. (2006). Macroscopic optical mapping of excitation in cardiac cell networks with ultra-high spatiotemporal resolution. Prog. Biophys. Mol. Biol. 92, 232–257.

Faivre, J.F., Forest, M.C., Gout, B., and Bril, A. (1999). Electrophysiological characterization of BRL-32872 in canine Purkinje fiber and ventricular muscle. Effect on early after-depolarizations and
regeneration and repolarization dispersion. Eur. J. Pharmacol. 383, 215–222.

Flytzanis, N.C., Bedbrook, C.N., Chu, H., Engvist, M.K., Xiao, C., Chan, K.Y., Stemberg, P.W., Arnold, F.H., and Gradinaru, V. (2014). Archaeorhodopsin variants with enhanced voltage-sensitive fluorescence in mammalian and Caenorhabditis elegans neurons. Nat. Commun. 5, 4894.

Gong, Y., Huang, C., Li, J.Z., Grewe, B.F., Zhang, Y., Eismann, S., and Schnitzer, M.J. (2015). High-speed recording of neural spikes in awake mice and flies with a fluorescent voltage sensor. Science 350, 1361–1366.

Gong, Y., Wagner, M.J., Zhong Li, J., and Schnitzer, M.J. (2014). Imaging neural spiking in brain tissue using FRET-opsin protein voltage sensors. Nat. Commun. 5, 3674.

Gwathmey, J.K., Copelas, L., MacKinnon, R., Schoner, F.J., Feliciano, M.D., Grossman, W., and Morgan, J.P. (1987). Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ. Res. 61, 70–76.

Herron, T.J., Lee, P., and Jalife, J. (2012). Optical imaging of voltage and calcium in cardiac cells & tissues. Circ. Res. 110, 609–623.

Hobai, J.A., and O’Rourke, B. (2001). Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. Circulation 103, 1577–1584.

Hochbaum, D.R., Zhao, Y., Farhi, S.L., Klopopke, N., Wery, C.A., Kapoor, V., Zou, P., Kralj, J.M., Macalurin, D., Smedemark-Margules, N., et al. (2014). All-optical electrophysiology in mammalian neurons using engineered microbial rhodopsins. Nat. Methods 11, 825–833.

Hortig-Vinagre, M.P., Zamora, V., Burton, F.L., Green, J., Gintant, G.A., and Smith, G.L. (2016). The use of ratiometric fluorescence measurements of the voltage sensitive dye Di-4-ANEPPS to examine action potential characteristics and drug effects on human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 154, 320–331.

Hou, J.H., Kralj, J.M., Douglass, A.D., Engert, F., and Cohen, A.E. (2014). Simultaneous mapping of membrane voltage and calcium in zebrafish heart in vivo reveals chamber-specific developmental transitions in ionic currents. Front. Physiol. 5, 344.

Jin, L., Han, Z., Platsa, J., Wooltorton, J.R., Cohen, L.B., and Pieribone, V.A. (2012). Single action potentials and subthreshold electrical evolutions imaged with a fluorescent protein voltage probe. Neuron 75, 779–785.

Johnston, C.M., Krafft, A.J., Russe, M.F., and Rog-Zielinska, E.A. (2018). A new look at the heart-cell novel imaging techniques. Herzschrittmacher Elektrophysiolog. 29, 14–23.

Kaab, S., Nuss, H.B., Chiamvimonvat, N., O’Rourke, B., Pak, P.H., Kass, D.A., Marban, E., and Tomasselli, G.F. (1996). Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ. Res. 78, 262–273.

Kastler, L., Tian, Q., Kaiser, E., Xian, W., Muller, A., Oberhofer, M., Ruppenthal, S., Sinnecker, D., Tsutsui, H., Miyawaki, A., et al. (2015). Genetically encoded voltage indicators in circulation Research. Int. J. Mol. Sci. 16, 21626–21642.

Lee, S., Geiler, T., Jung, A., Nakajima, R., Song, Y.K., and Baker, B.J. (2017). Improving a genetically encoded voltage indicator by modifying the cytoplasmic charge composition. Sci. Rep. 7, 8286.

Leighton-Mange, J.S., and Milan, D.J. (2014). Pluripotent stem cells as a platform for cardiac arrhythmia drug screening. Curr. Treat. Opt. Cardiovasc. Med. 16, 334.

Leighton-Mange, J.S., Mills, R.W., Maci, V.S., Jang, M.Y., Butte, F.N., Ellinor, P.T., and Milan, D.J. (2014). Rapid cellular phenotyping of human pluripotent stem cell-derived cardiomyocytes using a genetically encoded fluorescent voltage sensor. Stem Cell Rep. 2, 163–170.

Lou, S., Adam, Y., Weinstein, E.N., Williams, E., Williams, K.P., Nakajima, H., Libery, S., Madisen, L., Zeng, H., et al. (2016). Genetically targeted all-optical electrophysiology with a transgenic ce-dependent optapath mouse. J. Neurosci. 36, 11059–11073.

Lundby, A., Mutoh, H., Dimitrov, D., Akemann, W., and Knopfel, T. (2008). Engineering of a genetically encoded fluorescent voltage sensor exploiting fast Ci-VSP voltage-sensing movements. PLoS One 3, e2514.

Ma, J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J.A., Kamp, T.J., Kolaja, K.L., Swanson, B.J., and January, C.T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006–H2017.

Maddah, M., Heidmann, J.D., Marcegaglia, M., Walker, C.D., Bolouki, S., Conklin, B.R., and Lorenwe, K.E. (2015). A non-invasive platform for functional characterization of stem-cell-derived cardiomyocytes with applications in cardiotoxicity testing. Stem Cell Rep. 4, 621–631.

Mutoh, H., Perron, A., Dimitrov, D., Iwamoto, Y., Akemann, W., Chudakov, D.M., and Knopfel, T. (2009). Spectrally-resolved response properties of the three most advanced FRET based fluorescent protein voltage probes. PLoS One 4, e4555.

Nakajima, R., Jung, A., Yoon, B.J., and Baker, B.J. (2016). Optogenetic monitoring of synaptic activity with genetically encoded voltage indicators. Front. Synaptic Neurosci. 8, 22.

Nunes, S.S., Miklas, J.W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Masse, S., Gagliardi, M., Hsieh, A., et al. (2013). Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat. Methods 10, 781–787.

Olivi, M.T., Bartorelli, C., Polese, A., Fiorentini, C., Moruzzi, P., and Guazzi, M. (1976). Merocyanine 540 as an optical probe of transmembrane electrical activity in the heart. Science 191, 485–487.

Sanguinetti, M.C., and Jurkiewicz, N.K. (1991). Delayed rectifier outward K+ current is composed of two currents in guinea pig atrial cells. Am. J. Physiol. 260, H393–H399.

Sanguinetti, M.C., Jurkiewicz, N.K., Scott, A., and Segi, P.K. (1991). Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action. Circ. Res. 68, 77–84.

Scheel, O., Frech, S., Amuzescu, B., Esfeld, J., Lin, K.H., and Knott, T. (2014). Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology. Assay Drug Dev. Technol. 12, 457–469.

Shaheen, N., Shiti, A., Huber, I., Shnawi, R., Arbél, G., Gepstein, A., Setter, N., Goldfracht, I., Gruber, A., Chorna, S.V., et al. (2018). Human induced pluripotent stem cell-derived cardiac cell sheets expressing genetically encoded voltage indicator for pharmacological and arrhythmia studies. Stem Cell Rep. 10, 1879–1894.

Shnawi, R., Huber, I., Mazielis, L., Shaheen, N., Gepstein, A., Arbél, G., Tijssen, A.J., and Gepstein, L. (2015). Monitoring human-induced pluripotent stem cell-derived cardiomyocytes with genetically encoded calcium and voltage fluorescent reporters. Stem Cell Rep. 5, 582–596.
hypertrophic cardiomyopathy. PLoS One 11, e0168407.

Storace, D., Sephehri Rad, M., Kang, B., Cohen, L.B., Hughes, T., and Baker, B.J. (2016). Toward better genetically encoded sensors of membrane potential. Trends Neurosci. 39, 277–289.

Tsutsui, H., Higashijima, S., Miyawaki, A., and Okamura, Y. (2010). Visualizing voltage dynamics in zebrafish heart. J. Physiol. 588, 2017–2021.

Tu, C., Chao, B.S., and Wu, J.C. (2018). Strategies for improving the maturity of human-induced pluripotent stem cell-derived cardiomyocytes. Circ. Res. 123, 512–514.

van Opbergen, C.J.M., Koopman, C.D., Kok, B.J.M., Knopfel, T., Renninger, S.L., Orger, M.B., Vos, M.A., van Veen, T.A.B., Bakkers, J., and de Boer, T.P. (2018). Optogenetic sensors in the zebrafish heart: a novel in vivo electrophysiological tool to study cardiac arrhythmogenesis. Theranostics 8, 4750–4764.

Villette, V., Chavarha, M., Dimov, I.K., Bradley, J., Pradhan, L., Mathieu, B., Evans, S.W., Chamberland, S., Shi, D., Yang, R., et al. (2019). Ultrafast two-photon imaging of a high-gain voltage indicator in awake behaving mice. Cell 179, 1590–1608 e1523.

Zimmermann, W.H., Schneiderbanger, K., Schubert, P., Didie, M., Munzel, F., Heubach, J.F., Kostin, S., Neuhuber, W.L., and Eschenhagen, T. (2002). Tissue engineering of a differentiated cardiac muscle construct. Circ. Res. 90, 223–230.

Zou, P., Zhao, Y., Douglass, A.D., Hochbaum, D.R., Brinks, D., Werley, C.A., Harrison, D.J., Campbell, R.E., and Cohen, A.E. (2014). Bright and fast multicoloured voltage reporters via electrochromic FRET. Nat. Commun. 5, 4625.
Supplemental Information

Voltage Imaging of Cardiac Cells
and Tissue Using the Genetically Encoded
Voltage Sensor Archon1

Sanaya N. Shroff, Shoshana L. Das, Hua-an Tseng, Jad Noueiheid, Fernando Fernandez, John A. White, Christopher S. Chen, and Xue Han
Supplementary Information Guide

**Figure S1.** Related to Figure 2.  
Quantification of electrophysiological properties of non-expressing CMs compared to Archon1-expressing CMs.

**Table S1.** Related to Figures 2D,G,H, S1,S2.  
Statistical analyses for Figures 2D,G,H, S1, S2.

**Figure S2.** Related to Figure 2H.  
Archon1 allows robust measurement of action potentials under repeated and long-duration imaging.

**Table S2.** Related to Figure 3D,E.  
Statistical analyses for Figure 3D,E.

Transparent Methods

Supplementary References
Figure S1. Quantification of electrophysiological properties of non-expressing CMs compared to Archon1-expressing CMs. Related to Figure 2.

(A) Resting membrane potential (RMP, n = 7, 5 cells, respectively), ns, p > 0.05 in two-tailed t-test. (B) Action potential amplitude (n = 7, 5 cells, respectively), ns, p > 0.05 in two-tailed t-test. (C) Resistance (n = 6, 5 cells, respectively), ns, p > 0.05 in two-tailed t-test. (D) Rise time (n = 7, 5 cells, respectively), ns, p > 0.05 in two-tailed t-test. (E) APD90 (n = 7, 5 cells, respectively), ns, p > 0.05 in two-tailed t-test. (F) Beat period (n = 7, 5 cells, respectively), ns, p > 0.05 in two-tailed t-test. See full statistics in Table S1. Box plots represent 25th to 75th percentiles, with whiskers extending 1.5x the interquartile range, horizontal line represents median, each dot represents data from a single cell.
Table S1. Statistical analyses for Figure 2D, G, H, Figure S1, Figure S2

Two tailed student t-test for Figure 2D between rise time of CMs recorded with patch-clamp electrophysiology, Archon1, and downsampled patch-clamp electrophysiology.

| Comparison                      | p value   |
|---------------------------------|-----------|
| Ephys ↔ Downsampled Ephys       | 8.86E-03  |
| Ephys ↔ Archon1                 | 5.83E-05  |
| Downsampled Ephys ↔ Archon1     | 0.0584    |

Two tailed student t-test for Figure 2G between SNR of CMs recorded with patch-clamp electrophysiology, Di-8-ANEPPS, or Archon1.

| Comparison                      | p value   |
|---------------------------------|-----------|
| Ephys ↔ Di-8-ANEPPS             | 1.35E-08  |
| Di-8-ANEPPS ↔ Archon1           | 2.91E-07  |
| Ephys ↔ Archon1                 | 8.31E-04  |

Two tailed student t-test for Figure S1 comparing electrophysiological properties of Archon1-expressing vs. non-expressing cardiomyocytes

| Property                        | p value |
|---------------------------------|---------|
| Resting Membrane Potential      | 0.146   |
| Amplitude                       | 0.628   |
| Resistance                      | 0.861   |
| Rise Time                       | 0.905   |
| APD90                           | 0.934   |
| Period                          | 0.343   |
Repeated measures one-way ANOVA for Figure 2H of SNR per cell recorded repeatedly at t = 0, 1, 3 hours

SNR
Mauchly's Test of Sphericity

| Within Subjects Effect | Mauchly's W | Approx. Chi-Square | df | Sig. |
|-------------------------|-------------|--------------------|----|------|
| Time                    | 0.683       | 4.568              | 2  | 0.102*|

*Sphericity can be assumed

Repeated Measures ANOVA: Tests of Within-Subjects Effects

| Source | Assumption | Type III Sum of Squares | df | Mean Square | F     | Sig. | Partial Eta Squared |
|--------|------------|-------------------------|----|-------------|-------|------|---------------------|
| Time   | Sphericity Assumed | 23.928 | 2 | 11.964 | 0.201 | 0.819 | 0.015               |

One-way ANOVA for Figure S2D-F of SNR per waveform of cell recorded for 5 minutes

SNR

| Groups     | Count | Sum       | Average | Variance     |
|------------|-------|-----------|---------|--------------|
| 0 to 20s   | 18    | 444.1389  | 24.67438| 0.434717     |
| 100 to 120s| 18    | 445.103   | 24.72794| 0.226051     |
| last 20s   | 18    | 442.0286  | 24.55714| 0.665828     |

| Source of Variation | SS     | df   | MS      | F     | P-value | F crit |
|---------------------|--------|------|---------|-------|---------|--------|
| Between Groups      | 0.274723 | 2    | 0.137361| 0.310633| 0.73436 | 3.178799|
| Within Groups       | 22.55213 | 51   | 0.442199|       |         |        |
| Total               | 22.82686 | 53   |         |       |         |        |
Figure S2. Archon1 allows for robust measurement of action potentials under repeated and long-duration imaging. Related to Figure 2H.

(A-C) Representative optical voltage trace for an example CM recorded repeatedly at (A) t = 0hr, (B) t = 1hr, (C) t = 3hr. Electrically paced at 1Hz. Quantification of SNR for all repeatedly recorded cells in Figure 2H. (D-F) Archon1 optical voltage trace for CM recorded for 5 minutes continuously, electrically paced at 1Hz. (D) 0-20s; SNR: 24.67±0.659, mean±standard deviation, (E) 100-120s; SNR: 24.72 ±0.475, mean±standard deviation, (F) 280-300s; SNR: 24.56 ±0.816, mean±standard deviation. p = 0.734, one-way ANOVA. For full statistics see Table S1. All optical traces obtained at Image acquisition rate of 100Hz.
Table S2. Statistical analyses for Figure 3D,E.

All pairs Tukey HSD test for Figure 3D between %ΔAPD90 of CMs exposed to 0 (DMSO), 3, 10, 30 nM E-4031.

| E-4031 (nM) | 0      | 3      | 10     | 30     |
|------------|--------|--------|--------|--------|
| 0          | -0.10548 | 0.12918 | 0.30957 | 0.43012 |
| 3          | 0.12918 | -0.10548 | 0.07491 | 0.19546 |
| 10         | 0.30957 | 0.07491 | -0.10548 | 0.01507 |
| 30         | 0.43012 | 0.19546 | 0.01507 | -0.10548 |

| Nifedipine (nM) | 0     | 10    | 30    | 100   |
|----------------|-------|-------|-------|-------|
| 0              | -0.04047 | 0.05134 | 0.09180 | 0.22796 |
| 10             | 0.05134 | -0.04047 | -0.00001 | 0.13615 |
| 30             | 0.09180 | -0.00001 | -0.04047 | 0.09569 |
| 100            | 0.22796 | 0.13615 | 0.09569 | -0.04047 |

All pairs Tukey HSD test for Figure 3E between %ΔAPD50 of CMs exposed to 0 (DMSO), 10, 30, 100 nM Nifedipine.

| Group 1 | Group2 | Difference | Std Err Diff | Lower CL | Upper CL | p value |
|---------|--------|------------|--------------|----------|----------|---------|
| 0       | 3      | 0.2346604  | 0.0391640    | 0.1291829 | 0.4301378 | <.0001  |
| 0       | 10     | 0.4150448  | 0.0391640    | 0.3095673 | 0.5205222 | <.0001  |
| 0       | 30     | 0.5355928  | 0.0391640    | 0.4301154 | 0.6410703 | <.0001  |
| 3       | 10     | 0.1803844  | 0.0391640    | 0.0749070 | 0.2858619 | 0.0003  |
| 3       | 30     | 0.3009325  | 0.0391640    | 0.1954550 | 0.4064099 | <.0001  |
| 10      | 30     | 0.1205480  | 0.0391640    | 0.0150706 | 0.2260255 | 0.0198  |

| Group1 | Group2 | Difference | Std Err Dif | Lower CL | Upper CL | p value |
|--------|--------|------------|--------------|----------|----------|---------|
| 0      | 10     | 0.0918113  | 0.0150277    | 0.051338 | 0.1322844 | <.0001  |
| 0      | 30     | 0.1322704  | 0.0150277    | 0.091797 | 0.1727435 | <.0001  |
| 0      | 100    | 0.2684331  | 0.0150277    | 0.227960 | 0.3089062 | <.0001  |
| 10     | 30     | 0.0404590  | 0.0150277    | -0.00001 | 0.0809321 | 0.0501  |
| 10     | 100    | 0.1766218  | 0.0150277    | 0.136149 | 0.2170949 | <.0001  |
| 30     | 100    | 0.1361627  | 0.0150277    | 0.095690 | 0.1766358 | <.0001  |
Transparent Methods

Cell Source Details
iPSC cells I.D. Personal Genome Project (PGP1) were isolated from male, 53 years of age, fibroblasts. hMSCs were isolated from purchased Human Bone Marrow Mononuclear Cells (Lonza), from a male, 39.

Cell Preparation and Culture
iPSCs were screened for copy number variants and virtual karyotyping using Illumina HumanOmniExpress-12v1 arrays. iPSCs were maintained in complete mTeSR1 medium (Stem Cell) and differentiated in monolayers into CMs using RPMI 1640 Medium, GlutaMAX (Gibco) supplemented with B-27 Supplement, minus insulin (Gibco). CHIR99021 (12µM, Tocris) was added on Day 1 of differentiation to activate Wnt pathway, and IWP4 (5µM, Tocris) was added for Days 3 and 4 to inhibit Wnt pathway. Cells were switched to RPMI 1640 Medium, GlutaMAX containing standard B-27 Supplement (Gibco) on Day 10. Once spontaneous beating was observed, CMs were metabolically selected using glucose free, RPMI 1640 Medium (Gibco) supplemented with 4mM of DL-lactate (Sigma) for two days. Following selection, CMs were maintained in RPMI 1640, GlutaMAX supplemented with B-27 Supplement. hMSCs were maintained in DMEM, low glucose medium (Gibco) with 10% Fetal Bovine Serum (Sigma) and 1% Penicillin-Streptomycin (Gibco) and used from passage 6–9. All cells were kept at 37°C with 5.0% CO2.

Cardiomyocyte Transduction
CMs were replated onto Fibronectin, human (Corning) coated plates. 24 hours after replating, CAG-FLEX-Archon1-KGC-EGFP-ER2 rAAV2 (Archon1) (MOI: 2000-3000) and CMV-Cre AAV9 (Addgene) (MOI: 4000-6000) were added. After 2 days, viruses were washed out and CMs were maintained in RPMI 1640 supplemented with B27. Experiments were performed between days 7 and 14 post-transduction.

Engineered Cardiac Tissue Seeding
Engineered cardiac tissues were prepared as previously described (Boudou et al., 2012). Briefly, Polydimethylsiloxane micro-fabricated tissue gauges (µTUGs) were prepared by molding from SU-8 masters. µTUG devices were UV light sterilized then treated with 0.05% Pluronic F127 (Sigma) for 30 minutes to prevent cell and extracellular adhesion. CMs and hMSCs were dissociated and suspended together (8.4% CMs expressing Archon1, 75.6% non-expressing CMs, 16% hMSCs, total 1.2 million cells/ml) in a hydrogel consisting of 2.25mg/ml Collagen I, Rat Tail (Corning) and 0.5mg/ml human plasma fibrinogen (Sigma). The cell suspension was centrifuged into device microwells and excess was removed by dewetting. Hydrogels were polymerized at 37°C for 20 minutes and tissues were maintained in DMEM (Corning) 10% Fetal Bovine Serum (Sigma), 1% Penicillin-Streptomycin (Gibco), GlutaMAX Supplement (Gibco), MEM Non-Essential Amino Acid Solution (Gibco). Tissues were imaged on Day 6-9 post-seeding. 5µM MYK-461 (Cayman Chemical) was used to inhibit CM contraction during multi-cell imaging.

Electrophysiology
Two-photon microscopy was used for visually guided patch clamp recordings of CMs. CMs were visualized using the EGFP fluorescent marker bound to Archon1, and the electrode pipette was visualized by adding the orange fluorescent dye Alexa Fluor 568 hydrazide (Thermo Fisher Scientific) to the intracellular electrode solution (50µM). Imaging was performed using a two-photon microscope (Thorlabs) using a 20X, NA 1.0 (Olympus) objective lens. A mode-locked Ti:Sapphire laser (Chameleon Ultra II; Coherent) set to a wavelength of 900 nm was used to excite both the Alexa Fluor 568 and EGFP. Fluorescence was detected using two photo-multiplier tubes (Hamamatsu) equipped with 525/25nm and 607/35nm filters to separate emission from EGFP and Alexa Fluor 568, respectively.
Electrical recordings acquired simultaneously with optical recordings used the same imaging setup described in detail in the "Microscopy" section for the visualization of the patching process. The electrode pipette was visualized by adding the green fluorescent dye Alexa Fluor 488 hydrazide (Thermo Fisher Scientific) to the intracellular electrode solution (50µM). The electrode was placed in the on-cell configuration using 470 nm LED excitation, before switching to the far-red imaging of Archon1 and proceeding with the electrical recordings.

To verify that Archon1 does not alter CMs electrically, cells expressing Archon1 and non-expressing control cells were patched within the same monolayer. Differential interference contrast (DIC) microscopy (Olympus BX51W1) was used for visualizing the CMs and patch pipettes. CMs expressing Archon1 were identified using the EGFP tag.

CM monolayers on coverslips were immersed in the bath solution (140mM NaCl, 5.4mM KCl, 1mM MgCl₂, 10mM D-glucose, 1.8mM CaCl₂, 10mM HEPES; pH 7.4 with NaOH) (Yazawa, 2018). A silver-chloride wire placed inside the bath was used as the ground electrode. Intracellular membrane voltage recordings were carried out using patch clamp electrodes with resistance values between 8 MΩ and 12 MΩ. Electrodes were pulled using a horizontal puller (Sutter Instruments) using filamented, thin-wall glass (Sutter Instruments) and filled with the intracellular solution (120mM potassium D-gluconate, 15mM KCl, 4mM Na₂ATP, 2mM trisGTP, 4mM ditrisphosphocreatine, 10mM EGTA, 1mM CaCl₂, 10mM HEPES) (Yazawa, 2018). Electrodes were lowered into the bath approximately 200 µm above the coverslip surface using a micromanipulator (Sutter Instruments) and then slowly lowered to a cell. A small amount of positive pressure was used to push away debris and prevent clogging of the pipette tip. A 10 mV voltage step was used to measure seal resistance and the capacitance associated with the glass electrode. Upon seal formation (> 1GΩ) in the on-cell (i.e. cell-attached) configuration, capacitance compensation was used to eliminate the pipette capacitance. Small amounts of transient negative pressure were used to break the seal and establish whole cell recordings. The membrane voltage was recorded in current clamp with full bridge balance compensation and no injected current. Trace signals were amplified and low-pass filtered at 10 kHz before being digitized at 20 kHz. All electrophysiology was carried out using a Multiclamp 700B (Molecular Devices) and a Digidata 1440A (Molecular Devices).

**Di-8-ANEPPS**

Di-8-ANEPPS (Santa Cruz) was dissolved in Dimethyl Sulfoxide (DMSO, Thermo Fisher). CMs transduced with Archon1 were incubated with 10µM Di-8-ANEPPS, RPMI 1640, no phenol red medium (Gibco) and 0.05% F127 Pluronics for 15 minutes. After incubation, samples were washed 3x with RPMI 1640, no phenol red medium before imaging. Imaging was done both with spontaneously beating and electrically paced (0.5 - 3 Hz) cells. Cells with Di-8-ANEPPS were imaged using a 470 nm LED (ThorLabs Inc., M470L3) with a 570 nm LP dichroic (Olympus, OCT49005BX3) and a 620/60 nm (Olympus, OCT49005BX3 bandpass emission filter.

**Ion Channel Inhibitors**

E-4031 dihydrochloride (Abcam) and Nifedipine (Abcam) were dissolved in DMSO at 50mM and 100mM, respectively. Drug solutions were made by diluting stock solutions with RPMI, no phenol red medium to 20x the final drug treatment concentration. For all samples, 10 cells were imaged prior to drug treatment. Then, concentrated drug solution was added to samples to make final concentrations of 10nM, 30nM, and 100nM for E-4031 and 30nM, 100nM, and 300nM for Nifedipine. DMSO concentrations for all samples were 0.0003% or less, DMSO control was performed using 0.0003% DMSO. Samples were incubated at 37°C for 20 minutes with drug, and the 10 same cells were imaged. All cells were paced at 1Hz.
Microscopy
All optical recordings were acquired using a conventional one-photon widefield fluorescence microscope equipped with an ORCA Flash 4.0 V3 Digital CMOS camera (Hamamatsu Photonics K.K., C13440-20CU) or Hamamatsu ORCA Fusion Digital CMOS camera (Hamamatsu Photonics K.K., C14440-20UP), 10x NA0.3 CFI Plan Fluorite water immersion objective (Nikon), 40x NA0.8 CFI APO NIR water immersion objective (Nikon). Archon1’s green GFP fluorescence was imaged using a 470 nm LED (ThorLabs Inc., M470L3) with 470/25 nm bandpass excitation filter, 495 nm dichroic, and a 525/50 nm bandpass emission filter (Olympus, OCT49002BX3). Archon1’s far-red fluorescence was imaged using a 140 mW 637 nm laser (Coherent Obis 637-140X), 635 nm laser dichroic filter, and a 664 nm long pass emission filter (Olympus, OCT49006BX3) with 1x1 or 2x2 binning. Optical recordings were acquired at 50 or 100 Hz with HCImage Live (Hamamatsu Photonics K.K.) HC Image Live data were stored as multi-TIFF files and further analyzed offline in Fiji/ImageJ and MATLAB (Mathworks Inc.). Sample were maintained at 37°C throughout imaging using a heated stage. Samples were paced using an Ionoptix C-Pace EM using carbon electrodes made from carbon rods (Ladd Research) attached to platinum wires (Sigma) submerged in medium. Pacing was performed at 20V, with a 10ms duration, at indicated frequencies.

ROI identification
Images were imported into Fiji/ImageJ and ROIs were manually segmented by examining each time-series to identify areas with clear cell borders. Voltage traces for each ROI were extracted in Fiji/ImageJ and used for subsequent analyses.

Voltage trace processing
Before analysis, we pre-processed the fluorescence traces per the following: Di-8-ANEPPS traces were first inverted by multiplying -1 so that increases of membrane potential corresponded to increases in the trace value. The traces were then detrended using the MATLAB function “detrend” and rescaled so that the maximum intensity equaled 100 while the minimum intensity equaled zero. After rescaling, the Archon1 and Di-8-ANEPPS traces were resampled at 20kHz to match the sampling rate of electrophysiological recordings.

Rise time calculation
To calculate rise time, we first identified the peaks and valleys of each waveform. The peaks of each waveform were identified using the MATLAB function “findpeaks”, and the valleys were defined as the first data point before the peak with negative slope and with rescaled intensity value less than 50. To ensure that we captured the whole waveform, we excluded any peak that occurred within the first 0.5 seconds or within the last 1.5 seconds of recording. The rise time was defined as the duration between the take off point (10% above the valley) to 90% of the peak.

APD90 and APD50 calculation
To obtain the ADP90 for each waveform, we first calculated a threshold at 10% of the amplitude (the intensity difference between the peak and its prior valley) above the valley. We then identified two time points: the time point right before the intensity increased over the threshold during the rising phase, and the time point right after the intensity decreased below the threshold during the falling phase. The ADP90 was defined as the duration between these two time points. A similar calculation was conducted for determination of APD50 values, except with a threshold set at 50% of the amplitude above the valley.

Signal to noise ratio (SNR) calculation
To calculate the SNR, we divided the amplitude of each waveform (signal) by the noise, which we defined as the standard deviation of the 10 Hz high-pass-filtered trace.
Supplementary References

Boudou, T., Legant, W.R., Mu, A., Borochin, M.A., Thavandiran, N., Radisic, M., Zandstra, P.W., Epstein, J.A., Margulies, K.B., and Chen, C.S. (2012). A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues. Tissue Eng Part A 18, 910-919.

Yazawa, M., Morikawa, K., Song, L.J., Ronaldson-Bouchard, K., Vunjak-Novakovic, G. (2018). Electrophysiological recordings of cardiomyocytes isolated from engineered human cardiac tissues derived from pluripotent stem cells. Protocol Exchange. doi:10.1038/protex.2018.030.